1+ hour, 50+ min ago   (176+ words) Patrick Borgen, MD built Brooklyn's breast cancer program from 47 patients to 8000. Now he and Joshua Feinberg, MD discuss what surgery looks like next. The Moonlight Shift is available on YouTube and across MJH Life Sciences’ oncology platforms. New episodes, released…...

2+ week, 5+ day ago   (72+ words) Kathryn Eckert, DO, described how her breast surgery practice and imaging partners responded on day 1 of the Hologic Brevera needle recall. CancerNetwork: When the Hologic Brevera recall hit in January, how quickly did your institution feel the effects, and what…...

2+ week, 6+ day ago   (579+ words) A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice. Kathryn Eckert, DO, a breast surgeon at HMH’s Jersey Shore University Medical Center Harriet Borofsky, MD, medical director of…...

3+ week, 3+ day ago   (265+ words) CancerNetwork The FDA approval of gedatolisib (Revtorpyk) introduced an intravenous therapeutic option for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer after progressing on endocrine therapy 1While oral agents targeting the PI3K/AKT/mTOR pathway have historically been…...

3+ week, 5+ day ago   (321+ words) CancerNetwork Background Breast imaging is essential for breast cancer screening, diagnosis, and treatment, facilitating early detection and improving survival Despite its benefits, imaging disparities exist, driven partly by unequal access to mammography services; long travel distances reduce adherence and delay…...

3+ week, 5+ day ago   (216+ words) The FDA has approved the gedatolisib combination for HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i, based on the phase 3 VIKTORIA-1 trial. The FDA has approved gedatolisib (Revtorpyk) in combination with fulvestrant with or without palbociclib (Ibrance) for patients with hormone receptor…...

3+ week, 6+ day ago   (177+ words) CancerNetwork Background Cystic breast lesions, ranging from benign to malignant, are commonly encountered in clinical practice and may present diagnostic challenges Accurate characterization is essential to guide management We evaluated the diagnostic performance of an ultrasound artificial intelligence (AI) decision-support…...

3+ week, 6+ day ago   (291+ words) CancerNetwork Background Breast cancer remains the most prevalent cancer among US women, with approximately 300,000 new cases expected in 2024 While mammography reduces breast cancer mortality by 20% to 40%, the appropriate screening age for women in their 40s remains debated Recent 2024 guidelines recommend initiating…...

4+ week, 17+ hour ago   (322+ words) CancerNetwork Background CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are the first-line standard of care for hormone receptor–positive/HER2-negative (HER2–negative) metastatic breast cancer A growing body of real-world studies (RWS) has reported the comparative effectiveness of CDK4/6i plus endocrine therapy, but most have…...

4+ week, 2+ day ago   (311+ words) CancerNetwork Background While the RxPONDER trial was a landmark study demonstrating that Oncotype DX (ODX) can guide adjuvant chemotherapy use in postmenopausal women with 1 to 3 positive nodes and an ODX score of 25 or less, ODX was not predictive in premenopausal…...